ANDA 76629, held by Dr Reddys Labs SA. Ethinyl Estradiol; Norethindrone Acetate.
As of Nov 16, 2026, ANDA 76629 (Norethindrone Acetate And Ethinyl Estradiol), held by Dr Reddys Labs SA, was first approved by FDA on Mar 18, 2010, with 4 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 18, 2010 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Norethindrone Acetate And Ethinyl Estradiol0.02MG,0.03MG,0.035MG;1MG,1MG,1MG · tablet;oral-28 | Ethinyl Estradiol; Norethindrone Acetate | Discontinued |
| Apr 29, 2022 | Supplement 11Labeling · Standard review | Approved | None posted |
| Nov 9, 2021 | Supplement 10Labeling · Standard review | Approved | None posted |
| Aug 6, 2021 | Supplement 9Labeling · Standard review | Approved | None posted |
| Apr 13, 2015 | Supplement 5Labeling | Approved | None posted |
| Mar 18, 2010 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters